Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Hookipa Pharma Inc (NQ: HOOK )

0.9050 -0.0250 (-2.69%)
Streaming Delayed Price Updated: 11:44 AM EDT, May 6, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Hookipa Pharma Inc

< Previous 1 2 Next >
Stocks Creating Buzz Look Now: VTAK, AMST, HOOK, MULN, KAVL
Via AB Newswire
Topics Artificial Intelligence
Exposures Artificial Intelligence
HOOKIPA Pharma Announces Pivotal Phase 2/3 Trial Design for HB-200 in Combination with Pembrolizumab
From HOOKIPA Pharma Inc.
Via GlobeNewswire
HOOKIPA Pharma Announces FDA Clearance of its Investigational New Drug Application for HB-700 for the Treatment of KRAS-Mutated Cancers
From HOOKIPA Pharma Inc.
Via GlobeNewswire
HOOKIPA Pharma Announces Grant of Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
From HOOKIPA Pharma Inc.
Via GlobeNewswire
HOOKIPA Pharma to Host Investor Call on HB-200 and Planned Path to Registration
From HOOKIPA Pharma Inc.
Via GlobeNewswire
HOOKIPA Pharma Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights
From HOOKIPA Pharma Inc.
Via GlobeNewswire
HOOKIPA Pharma to Participate in Leerink Partners Global Biopharma Conference
From HOOKIPA Pharma Inc.
Via GlobeNewswire
HOOKIPA Pharma Provides Update on Business Priorities and Oncology Partnership Programs
From HOOKIPA Pharma Inc.
Via GlobeNewswire
HOOKIPA Pharma Appoints Mark Winderlich as Chief Development Officer to Lead Clinical Research and Development Organization
From HOOKIPA Pharma Inc.
Via GlobeNewswire
HOOKIPA Pharma Announces $21.25 Million Equity Investment from Gilead Sciences
From HOOKIPA Pharma Inc.
Via GlobeNewswire
HOOKIPA Pharma Announces FDA Clearance of its Investigational New Drug Application for HB-500 for the Treatment of Human Immunodeficiency Virus
From HOOKIPA Pharma Inc.
Via GlobeNewswire
HOOKIPA Pharma Reports Third Quarter 2023 Financial Results and Recent Business Highlights
From HOOKIPA Pharma Inc.
Via GlobeNewswire
HOOKIPA Pharma Presents Positive Biomarker and Translational Data on HB-200 Monotherapy at Society for Immunotherapy of Cancer 2023
From HOOKIPA Pharma Inc.
Via GlobeNewswire
HOOKIPA Pharma to Report Third Quarter 2023 Financial Results and Recent Business Highlights on November 9, 2023
From HOOKIPA Pharma Inc.
Via GlobeNewswire
HOOKIPA Pharma Presents Additional Preliminary Phase 2 Data on HB-200 in Combination with Pembrolizumab as First-Line Treatment in Patients with HPV16+ Head and Neck Cancers at European Society for Medical Oncology Congress 2023
From HOOKIPA Pharma Inc.
Via GlobeNewswire
HOOKIPA Pharma announces publication of preclinical data of hepatitis B virus (HBV) therapeutic vaccine developed in collaboration with Gilead Sciences
From HOOKIPA Pharma Inc.
Via GlobeNewswire
HOOKIPA Announces Executive Leadership Change
From HOOKIPA Pharma Inc.
Via GlobeNewswire
HOOKIPA Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
From HOOKIPA Pharma Inc.
Via GlobeNewswire
HOOKIPA Pharma to participate in upcoming investor conferences in September
From HOOKIPA Pharma Inc.
Via GlobeNewswire
HOOKIPA Pharma Reports Second Quarter 2023 Financial Results and Recent Business Highlights
From HOOKIPA Pharma Inc.
Via GlobeNewswire
HOOKIPA Pharma to Report Second Quarter 2023 Financial Results and Recent Business Highlights on August 10, 2023
From HOOKIPA Pharma Inc.
Via GlobeNewswire
HOOKIPA Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
From HOOKIPA Pharma Inc.
Via GlobeNewswire
HOOKIPA Pharma Announces Pricing of $50.0 Million Public Offering of Common Stock and Non-Voting Convertible Preferred Stock
From HOOKIPA Pharma Inc.
Via GlobeNewswire
HOOKIPA Pharma Announces Positive Preliminary Phase 2 Data on HB-200 in Combination with Pembrolizumab in Patients with HPV16+ Head and Neck Cancers
From HOOKIPA Pharma Inc.
Via GlobeNewswire
HOOKIPA Pharma Reports First Quarter 2023 Financial Results and Recent Business Highlights
From HOOKIPA Pharma Inc.
Via GlobeNewswire
HOOKIPA Announces First Person Dosed in Phase 1a/b Clinical Trial of HB-400, in Collaboration with Gilead, for Treatment of Hepatitis B
From HOOKIPA Pharma Inc.
Via GlobeNewswire
HOOKIPA Pharma to Participate in Upcoming Investor Conferences in May
From HOOKIPA Pharma Inc.
Via GlobeNewswire
HOOKIPA Pharma to Report First Quarter 2023 Financial Results and Recent Business Highlights on May 11, 2023
From HOOKIPA Pharma Inc.
Via GlobeNewswire
HOOKIPA to Present a Trial in Progress Poster on its Prostate Cancer Phase 1/2 Clinical Trial at ASCO
From HOOKIPA Pharma Inc.
Via GlobeNewswire
HOOKIPA Pharma to Participate in the Van Lanschot Kempen Life Sciences Conference
From HOOKIPA Pharma Inc.
Via GlobeNewswire
< Previous 1 2 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.